Form 4: Agios Pharmaceuticals Director David Schenkein Executes Stock Option and Sells Shares

Director David Schenkein exercised stock options and sold shares of Agios Pharmaceuticals on February 27, 2024.

Summary

• On February 27, 2024, David P. Schenkein, a director of Agios Pharmaceuticals, exercised stock options to acquire 11,858 shares and 57,471 shares of common stock at a price of $31.64 per share.
• Following the exercise of these options, Schenkein sold 11,858 shares at a weighted average price of $33.6, with prices ranging from $33.02 to $34.41.
• He also sold 57,471 shares at a weighted average price of $34.89, with prices ranging from $34.64 to $35.28.
• After these transactions, Schenkein directly owns 122,854 shares of Agios Pharmaceuticals common stock.
• Schenkein also indirectly owns 270,772 shares through the David P. Schenkein 2004 Revocable Trust and 79,082 shares through the Amy P. Schenkein 2004 Revocable Trust.

Sentiment

Score: 5

Explanation: This is a neutral disclosure of stock transactions. It doesn't inherently indicate positive or negative sentiment about the company's prospects.

Industry Context

This Form 4 filing is a routine disclosure of insider transactions, providing transparency to the market regarding the trading activities of company directors. It's common for executives to exercise stock options and sell shares for personal financial management.

Comparison to Industry Standards

• Insider trading activity is a common occurrence in publicly traded companies.
• Form 4 filings are standard practice and are used to ensure transparency and prevent illegal insider trading.
• The details provided in this filing are consistent with standard reporting requirements for insider transactions.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the change in ownership.
• The impact on employees, customers, suppliers, and creditors is likely negligible.

Key Dates